Author

A. Creanga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 8 Assay:proteomics· 5 Organism:mouse· 4 Organism:virus· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2

Frequent Co-Authors

A. Pegu· 5 shared J. R. Mascola· 5 shared M. Kanekiyo· 5 shared Y. Tsybovsky· 5 shared B. S. Graham· 4 shared R. A. Gillespie· 4 shared T. Stephens· 4 shared A. B. McDermott· 3 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

A. Pegu

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses

S. M. Moin, J. C. Boyington, S. Boyoglu-Barnum, R. A. Gillespie, G. Cerutti, C. S.-F. Cheung, A. Cagigi, J. R. Gallagher, J. Brand, M. Prabhakaran, Y. Tsybovsky, T. Stephens, B. E. Fisher, A. Creanga, S. Ataca, , M. Kanekiyo

This study shows that co-immunization with stem immunogens from group 1 and 2 influenza A HAs elicits cross-group neutralizing antibodies and protective immunity in multiple animal models.

bioRxiv · Feb 11, 2022 · PreprintImmunology

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability

W. Shi, L. Wang, T. Zhou, M. Sastry, E. S. Yang, Y. Zhang, M. Chen, X. Chen, M. Choe, A. Creanga, K. Leung, A. S. Olia, A. Pegu, R. Rawi, C.-H. Shen, , P. D. Kwong

This paper identifies an antibody, WS6, from a mouse immunized with SARS-CoV-2 spike mRNA, which neutralizes diverse beta-coronaviruses by targeting a conserved helical epitope on the S2 subunit.

bioRxiv · Jan 25, 2022Immunology

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

T. Zhou, L. Wang, J. Misasi, A. Pegu, Y. Zhang, D. R. Harris, A. S. Olia, C. A. Talana, E. S. Yang, M. Chen, M. Choe, W. Shi, I.-T. Teng, A. Creanga, C. Jenkins, , P. D. Kwong

The paper identifies potent monoclonal antibodies that neutralize the B.1.1.529 SARS-CoV-2 variant and reveals structural mechanisms enabling their effectiveness.

bioRxiv · Dec 27, 2021Immunology

Structure-based design of stabilized recombinant influenza neuraminidase tetramers

D. Ellis, J. Lederhofer, O. J. Acton, Y. Tsybovsky, S. Kephart, C. Yap, R. A. Gillespie, A. Creanga, T. Stephens, D. Pettie, M. Murphy, A. J. Borst, Y.-J. Park, K. K. Lee, B. S. Graham, , M. Kanekiyo

This study designs stabilized recombinant influenza neuraminidase tetramers by uncovering structural principles and improving thermal stability and antibody affinity.

bioRxiv · May 17, 2021Microbiology

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

V.-V. Edara, L. Lai, M. Sahoo, K. Floyd, M. Sibai, D. Solis, M. W. Flowers, L. Hussaini, C. R. Ciric, S. Bechnack, K. Stephens, E. B. Mokhtari, P. Mudvari, A. Creanga, A. Pegu, , M. Suthar

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

bioRxiv · May 9, 2021 · PreprintImmunology

CCR2-dependent monocyte-derived cells restrict SARS-CoV-2 infection

A. Vanderheiden, J. Thomas, A. L. Soung, M. E. Davis-Gardner, K. Floyd, F. Jin, D. A. Cowan, K. Pellegrini, A. Creanga, A. Pegu, A. Derrien-Colemyn, P.-Y. Shi, A. Grakoui, R. S. Klein, S. E. Bosinger, , M. S. Suthar

This study identifies a CCR2-dependent monocyte-derived cell mechanism that restricts SARS-CoV-2 infection and inflammation in the lungs of mice.

bioRxiv · May 3, 2021 · PreprintImmunology

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

L. VanBlargan, L. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. Whitener, L. Droit, I. Aziati, P.-Y. Shi, A. Creanga, , M. Diamond

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 26, 2021Microbiology

Using Neutralization Landscapes to enumerate Antibody Behavior and Decompose Antibody Mixtures

T. Einav, A. Creanga, S. F. Andrews, A. B. McDermott, M. Kanekiyo

The paper introduces a Neutralization Landscape to analyze antibody-virus interactions and decompose antibody mixtures targeting influenza hemagglutinin stem proteins.

bioRxiv · Aug 28, 2020Immunology

Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines

S. Boyoglu-Barnum, D. Ellis, R. A. Gillespie, G. B. Hutchinson, Y.-J. Park, S. M. Moin, O. Acton, R. Ravichandran, M. Murphy, D. Pettie, N. Matheson, L. Carter, A. Creanga, M. J. Watson, S. Kephart, , M. Kanekiyo

Nanoparticle immunogens with four seasonal influenza hemagglutinins elicit neutralizing antibodies against both the head and stem, providing broad protection against diverse influenza strains.

bioRxiv · May 30, 2020 · PreprintImmunology

A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies

A. Creanga, R. A. Gillespie, B. E. Fisher, S. F. Andrews, L. Hatch, T. Stephens, Y. Tsybovsky, M. C. Crank, A. B. McDermott, J. R. Mascola, B. S. Graham, M. Kanekiyo

The paper develops a fluorescent reporter virus panel to enable high-throughput neutralization profiling of influenza antibodies without requiring high-containment labs.

bioRxiv · Feb 24, 2020Immunology